S
Shorla Oncology
At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers.
About Shorla Oncology
At Shorla Oncology we develop and commercialize innovative oncology drugs. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments.
Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 67.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Medical Research, Oncology, Medical & Healthcare, Patient Engagement, Tech for Patients, Biotech and Pharma, biotech medtech and e-health, Woman Founder, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jan 2026 | $20M | — | Undisclosed | ↗ |
| SERIES BOther financing | Sep 2025 | — | — | Enterprise Ireland | — |
Growth signals
Latest recorded traffic for Shorla Oncology is 100 monthly website visits, down 33.3% over the last three months. Shorla Oncology's team grew 4.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shorla Oncology in the Cloghjordan ecosystem
The Shorla Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Seroba Life Sciences
Enterprise Ireland
Kurma Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shorla Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shorla Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









